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Abstract Everolimus is a mammalian target of rapamycin
(mTOR) inhibitor approved for the treatment of advanced
renal cell carcinoma, pancreatic neuroendocrine tumors,
subependymal giant cell astrocytoma associated with tuber-
ous sclerosis complex, renal angiomyolipoma and tuberous
sclerosis complex, and, in combination with exemestane, for
hormone receptor-positive HER2-negative advanced breast
cancer after failure of treatment with letrozole or
anastrozole. Results from the phase III BOLERO-2 trial
demonstrated that everolimus in combination with
exemestane provided significant clinical benefit to patients
with advanced hormone receptor-positive breast cancer. Al-
though everolimus is generally well tolerated, as with most
therapies administered in an advanced cancer setting, drug-
related adverse events (AEs) inevitably occur. Most com-
mon AEs observed in the everolimus studies include stoma-
titis, rash, infection, noninfectious pneumonitis, and
hyperglycemia. Clinical awareness and early identification
of such AEs by oncology nurses are essential to dosing
(interruptions, reduction, and treatment discontinuation);
quality of life; and, ultimately, patient outcomes. Because
everolimus has already been shown to significantly improve
clinical efficacy in patients with advanced breast cancer, a
proactive approach to the practical management of AEs
associated with this mTOR inhibitor as well as other most
common AEs observed in this patient population has been
reviewed and outlined here.
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Introduction
In 2012, an estimated 229,060 new cases of invasive breast
cancer (BC) are expected in the USA, including 2,190 cases
occurring in men [1]. For women with hormone receptor
(HR)-positive BC (approximately 70 % of patients with
BC), effective treatment options in the metastatic or locally
advanced setting are currently limited [2,3]. Although sub-
stantial decreases in incidence were observed between 2002
and 2003 (largely because of reductions in use of hormone
replacement therapy), the annual incidence rate since 2003
remains relatively unchanged [4]. Metastatic BC represents
approximately 5 % of all BC cases [4], and 39,920 BC
deaths are expected in 2012 [1]. The use of endocrine
therapies in the advanced HR-positive BC setting has sig-
nificantly improved clinical outcomes in women; however,
many patients fail to respond to first-line treatment or expe-
rience disease progression after an initial response [5–9].
Consequently, the continuing development of novel thera-
pies for the treatment of advanced HR-positive BC remains
of significant importance in the area of oncology.
New therapeutic strategies include the use of targeted
agents with varying mechanisms of action. As a class,
mammalian target of rapamycin (mTOR) inhibitors exhibit
significant clinical antitumor activity in a wide variety of
cancer types, including renal cell carcinomas (RCC), mantle
cell lymphoma, pancreatic neuroendocrine tumors, metastat-
ic sarcomas, and metastatic BC [10–19]. mTOR forms an
important component of the phosphoinositide 3-kinase/Akt
signaling pathway that mediates cell growth and prolifera-
tion, and dysregulation of this pathway is observed in many
cancers, including BC [20,21].
Oral mTOR inhibitor everolimus (Afinitor®) received
approval in 2009 from the US Food and Drug Administra-
tion (FDA) for treatment of advanced RCC after failure of
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sorafenib or sunitinib [22]. Everolimus received subsequent
approval from the FDA for the treatment of advanced pancre-
atic neuroendocrine tumors that are unresectable, locally ad-
vanced, or metastatic and for the treatment of subependymal
giant cell astrocytoma associated with tuberous sclerosis com-
plex in patients who require therapeutic intervention but are
not amenable to surgery [22]. In 2012, everolimus was ap-
proved by the FDA for the treatment of adults with renal
angiomyolipoma and tuberous sclerosis complex not requir-
ing immediate surgery and, in combination with exemestane,
for the treatment of advancedHR-positive HER2-negative BC
after failure of treatment with letrozole or anastrozole [22].
The European Medicines Agency has also approved
everolimus for the management of tumors and conditions de-
scribed above. Additionally, low-dose everolimus (Zortress®)
in combination with basiliximab and concurrently with reduced
doses of cyclosporine and corticosteroids received FDA ap-
proval in 2010 for the prevention of organ rejection in kidney
transplant recipients [23] and Certican® (worldwide) in com-
bination with cyclosporine was approved in 2003 for the
prevention of organ rejection in heart, liver, and kidney
transplant recipients [24].
More recently, results from the pivotal phase III Breast
Cancer Trials of Oral Everolimus (BOLERO)-2 study dem-
onstrated everolimus in combination with the endocrine
agent exemestane significantly extended progression-free
survival (PFS) compared with placebo plus exemestane in
women with advanced HR-positive, HER2-negative BC
[17,18]. Patient-centered strategies should be devised to
manage the often-inevitable adverse events (AEs) associated
with any specific cancer therapy. In this article, safety data
and previous clinical experience will be used as a basis to
describe AE management recommendations for patients
with BC who receive everolimus.
BOLERO-2 trial summary
BOLERO-2 was a phase III, randomized, double-blind,
placebo-controlled, multicenter study. conducted at 189 sites
worldwide (NCT00863655) [17,18]. A total of 724 patients
with postmenopausal advanced HR-positive, HER2-negative
BC refractory to previous letrozole or anastrozole were en-
rolled and those who met the study criteria were randomly
assigned (2:1) to receive oral everolimus 10 mg/day plus oral
exemestane 25 mg/day (n=485) or placebo plus oral
exemestane 25 mg/day (n=239) [17,18]. An interim analysis
based upon 7.1 months of follow-up determined that
everolimus plus exemestane significantly improved PFS com-
pared with exemestane alone (6.9 vs. 2.8 months, respectively;
hazard ratio=0.43; 95 % CI 0.35–0.54, p<0.001, local assess-
ment) [17].With 12months ofmedian follow-up, PFS based on
local investigator radiology assessment was 7.4 months for
everolimus plus exemestane versus 3.2 months for exemestane
only (hazard ratio=0.44; 95 % CI 0.36–0.53; p<0.001) [18].
Recently, an 18-month follow-up analysis determined that the
median PFS was 7.8 months versus 3.2 months (hazard ratio=
0.45; 95 % CI 0.38–0.54, p<0.001 local assessment) for com-
bination versus exemestane-only therapy, respectively (p<
0.001) [25]. Overall AEs observed in BOLERO-2 at the interim
analysis (7.1 months of follow-up) (Table 1) [17] were consis-
tent to AE rates observed at the 12- and 18-month follow-ups
[18,25] as well as with those previously reported with mTOR
inhibitors [10,11].
Potential adverse events encountered by the patient
Recognizing the unique AEs associated with anticancer
agents allows providers to individualize treatment plans
and thereby limit AEs that may decrease a patient’s ability
to complete a full course of therapy. Oncology professionals
involved in the day-to-day care of patients need to accurate-
ly recognize AEs associated with specific cancer therapies
and incorporate complementary supportive care treatments
to monitor, assess, and manage symptoms. Notably, the
Oncology Nursing Society (ONS) has played a critical role
in evaluating the array of available clinical evidence associ-
ated with the treatment of cancer therapy-related AEs. The
following discussion of the most commonly observed AEs in
the BOLERO-2 study based on the published report [17] and
the proposed management strategies is based on the efforts of
the ONS, who provided evidence-based management strate-
gies, together with a current review of the literature.
Class-specific adverse events associated with everolimus
combination therapy observed in the BOLERO-2 study
Stomatitis
Stomatitis, or oral mucositis, refers specifically to inflamma-
tory diseases of the mouth, including mucosa, dentition,
periapical abscesses, and periodontium. Such ailments can
impair a patient’s ability to eat, swallow, and talk and can cause
significant pain. Stomatitis is characterized by ulceration in the
oroesophageal mucosa, resulting in pain, erythema, dysphagia,
and occasionally bleeding [26,27]. Onset typically occurs early
(≤1 month after treatment initiation) and is transient [28,29].
The condition is also a common toxicity associated with che-
motherapy or radiation therapy, occurring as nonspecific ulcer-
ations for which localized palliative treatments and systemic
analgesics are generally applied [28,30]. In contrast to stoma-
titis associated with chemotherapy or radiation therapy, stoma-
titis associated with mTOR therapy has an inflammatory
component often clinically mimicking aphthous stomatitis
(commonly known as canker sores) and is differentiated from
lesions of viral etiology by their localization to the nonkeratinized
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movable oral and oropharynx mucosa, as opposed to the mucosa
of the palate, gingiva, or dorsal tongue surface [28,31]. These
differences also suggest that the aphthous-like lesions observed
with mTOR inhibitors differ from the lesions observed with
cytotoxic agents [28], so management strategies to prevent or
treat mTOR inhibitor associated stomatitis also must be
distinguished.
Management recommendations
Because stomatitis is a common AE (Table 1) experienced
by patients treated with everolimus [27], prophylactic treat-
ment and early recognition of this AE is highly important.
Early and active management includes the promotion of
good oral hygiene: consistent, regular, and thorough
brushing with a soft toothbrush that is changed on a regular
basis; daily flossing; frequent rinsing with bland rinses such
as sterile water, normal saline, or sodium bicarbonate; and
use of oral moisturizers [27,32].
Based on the clinical trial experience with patients treated
with everolimus, various management strategies depending
on the grade of stomatitis observed are recommended
(Table 2) [22]. The prescribing information for everolimus
specifically recommends that rinse formulations that contain
alcohol should be avoided [22]. The use of toothpastes
that are strong-flavored and that contain sodium lauryl
sulfate are not advised; milder, sodium lauryl sulfate-
free toothpaste (e.g., children’s flavors) should be used
instead [28]. Overall, oncology nurses should work to
promote an oral program that addresses basic oral needs
to help reduce the amount of microbial flora, reduce
pain and bleeding, and prevent infection. Patients also
should be advised to avoid acidic, spicy, and hard or
crunchy foods and to consume foods that are tepid
rather than hot in temperature to prevent the potential
for mechanical injury [28,30].
Early recognition and immediate effective treatment of
stomatitis is essential to reduce the number and severity of
ulcers. Although experience in managing everolimus-
associated stomatitis is limited, it is recommended that top-
ical corticosteroids and mouthwashes be used, similar to
those managed with chemotherapy induced stomatitis [27].
Consistently, standard treatment options include topical
high-potency corticosteroids (e.g., dexamethasone,
0.1 mg/mL; clobetasol gel, 0.05 %), topical nonsteroi-
dal anti-inflammatories (e.g., amlexanox, 5 % oral
paste), and topical anesthetics (“miracle” or “magic”
mouthwashes typically containing viscous lidocaine, di-
phenhydramine, and an antacid such as aluminum hy-
droxide or magnesium hydroxide), and nonimidazole
antifungals also may be appropriate for some patients
[27,28]. Agents containing hydrogen peroxide, iodine,
and thyme derivatives should be avoided in patients
with stomatitis [22,27]. L-Lysine 500 mg/day orally,
originally used for recurrence of herpes simplex infec-
tions, may also be beneficial in patients with recurring
oral ulcers [33].
Rash
Rash induced by treatment with mTOR inhibitors (Table 1)
typically occurs as maculopapular or papulopustular lesions,
often with pruritus, and erythematous papules or pustules
usually constitute the primary lesion morphology [34,35].
Rash primarily occurs on the trunk, scalp, face, and neck, with
extremities commonly involved [34,35]. The condition gen-
erally appears during the first months of everolimus treatment
and is most often grade 1 to 2 in severity [34,35].
Table 1 Incidence of any-grade
AEs occurring in ≥30 % or grade
3 or 4 AEs occurring in ≥3 % of
patients enrolled in BOLERO-2
(interim analysis, 7.1 months of
follow-up) [17]
aData on file, Novartis Pharma-
ceuticals Corporation. Includes
all infections and infestations as
defined by CTCAE criteria.
Note that all other AEs in this
table refer to specific preferred






Preferred term All grades Grade 3 Grade 4 All grades Grade 3 Grade 4
Stomatitis 56 8 0 11 1 0
Infectiona 44 4 2 21 2 0
Rash 36 1 0 6 0 0
Fatigue 33 3 <1 26 1 0
Diarrhea 30 2 <1 16 1 0
Dyspnea 18 4 0 9 1 <1
Anemia 16 5 1 4 <1 <1
Aspartate aminotransferase
increased
13 3 <1 6 1 0
Hyperglycemia 13 4 <1 2 <1 0
Pneumonitis 12 3 0 0 0 0
Alanine aminotransferase
increased
11 3 <1 3 2 0
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Management recommendations
Patient awareness and early intervention is important for
managing rash. Patients should be informed of the possibil-
ity of developing rash and should promptly report the first
signs or symptoms in order to initiate early intervention
[35]. Patients should also be educated on the need for
moisturizing frequently; using a thick, alcohol-free emol-
lient cream such as Eucerin®, Aquaphor®, or Cetaphil®;
taking short, lukewarm showers; using mild moisturizing,
fragrance-free soap; and bathing in lukewarm water with
one to two cups of baking soda or Aveeno® bath treatment
added to the water [36]. Patients should also be advised to
use a sunscreen of SPF 15 or higher, preferably containing
zinc oxide or titanium dioxide, in order to minimize sun
exposure [36]. Management strategies when rash develops
should be based on clinical phenotype [35]. For grade 1
papulopustular rash, a course of topical low- to
moderate-strength corticosteroid and topical antibiotics
should be sufficient; for grade 3 or intolerable grade 2
rashes, oral antibiotics for 2 to 4 weeks are advocated.
For grade 1 maculopapular rash, topical low- to
moderate-strength corticosteroids and oral antihistamines
should be considered; for grade 3 or intolerable grade 2
rashes, oral corticosteroids and dose reduction/interruption
may be required [35].
Hyperglycemia
Hyperglycemia is characterized by an abnormally high con-
centration of glucose in the blood plasma. According to the
American Diabetes Association, this is generally a fasting
glucose level >130 mg/dL or postprandial level >180 mg/dL
[37]. Symptoms of hyperglycemia include frequent urina-
tion, increased thirst, fatigue, blurred vision, weight loss,
headaches, and difficulty concentrating. A common toxicity
associated with treatment with mTOR inhibitors (Table 1),
hyperglycemia is generally well tolerated with a low inci-
dence of treatment discontinuation among patients with
cancer [10,17,38,39].
Management recommendations
Monitoring of fasting serum glucose is recommended before
the start of anticancer therapy and periodically thereafter
[27]. Optimal glycemic control should be achieved before
initiating therapy with an mTOR inhibitor and the patient be
made aware of symptoms that may develop. For patients
with glucose levels greater than the upper limit of normal
(160 mg/dL; grade 1 hyperglycemia), no treatments or dose
modifications are recommended [27]. Patients with glucose
levels of >160–250 mg/dL (grade 2), >250–500 mg/dL
(grade 3), or >500 mg/dL (grade 4) should be treated
according to the American Diabetes Association and Euro-
pean Association for the Study of Diabetes consensus algo-
rithm (Fig. 1) [27,40].
As a general strategy, a patient who develops hypergly-
cemia should be recommended to drink plenty of water,
exercise regularly, and reduce dietary amounts of carbohy-
drates and sugar [37]. In severe cases of hyperglycemia, oral
antidiabetics may be administered [37,41].
Noninfectious pneumonitis
Noninfectious pneumonitis is a class effect of mTOR inhibi-
tors (Table 1) characterized by a nonmalignant infiltration of
the lungs [42–44]. Current evidence suggests this agent-
related condition may be immunologically mediated [27,44].
Nonspecific respiratory signs and symptoms of pneumonitis
include cough, dyspnea, hypoxia, and occasionally pleural
Table 2 Recommended clinical management strategy: stomatitis [22]
Grade Symptoms Management Everolimus dose modification
1 Minimal (normal diet) • Manage with nonalcoholic or salt water (0.9 %)
mouth wash several times a day
• No dose adjustment required
2 Symptomatic but can eat
and swallow modified diet
• Temporary dose interruption until
recovery to grade ≤1
• Manage with topical analgesic mouth
treatments (e.g., benzocaine, butyl
aminobenzoate, tetracaine hydrochloride,
menthol, or phenol) with or without
topical corticosteroids (i.e., triamcinolone
oral paste)
• Reinitiate everolimus at the same
dose
• If stomatitis recurs at grade 2,
interrupt dose until recovery to
grade ≤1. Reinitiate everolimus at a
lower dose
• Avoid agents containing alcohol,
hydrogen peroxide, iodine, and thyme
derivatives
3 Symptomatic and unable to
adequately eat or hydrate orally
• Temporary dose interruption until
recovery to grade ≤1. Reinitiate
everolimus at a lower dose
4 Severe (symptoms are life threatening) • Discontinue everolimus and treat
with appropriate medical therapy
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effusion, although some patients remain asymptomatic. Com-
mon radiographic changes observed with mTOR inhibitor-
associated pneumonitis include ground-glass opacities and
focal consolidation, predominantly in the lower lobes [42,44].
Management recommendations
For patients with respiratory symptoms (cough, dyspnea
during exertion or at rest) or with documented multiple lung
metastases, a baseline computed tomography scan and pul-
monary function tests should be performed before initiation
of treatment with everolimus. If predicted single breath
transfer factor is <40 %, everolimus therapy should not be
initiated until pulmonary function test results have normal-
ized [27]. If no pulmonary compromise exists, baseline com-
puted tomography scans may be obtained at the physician’s
discretion [27]. The potential diagnosis of noninfectious pneu-
monitis should also be investigated in patients with nonspecific
respiratory signs and symptoms during everolimus treatment.
Radiographic imaging should be performed and bronchoalve-
olar lavage may be useful to rule out infection and evaluate
lung inflammation [27]. Therapy should be interrupted and
corticosteroid treatment initiated if a patient’s symptoms are
moderate to severe [27]. Upon resolution of these symptoms,
everolimus can be reinitiated at a reduced dose of 5 mg/day.
The everolimus package insert also contains a clinical man-
agement strategy for the treatment of everolimus-related
noninfectious pneumonitis (Table 3) [22].
Infection
Infection is a common AE reported in patients treated with
everolimus (Table 1) [22,34]. The innate immunosuppres-
sive properties of everolimus may predispose patients to
bacterial, fungal, viral, or protozoal infections including
pneumonia, sepsis, mycobacterial infections, aspergillosis,
candidiasis, and reactivation of the hepatitis B virus. In the
phase III RECORD-1 trial of everolimus (10 mg/day) in
advanced RCC, everolimus-related severe infection was
reported, including infection associated with fatal respirato-
ry failure or sepsis. In BOLERO-2, sepsis caused two deaths
[17]. Therefore, professionals should be vigilant in evaluat-
ing for signs and symptoms of infection with immediate
appropriate treatment taken.
Management recommendations
In order to identify patients at greater risk for developing
infection, a full medical history of prior infection should be
obtained and laboratory tests conducted before commencing
Diagnosis
No Yesa
Lifestyle intervention + metformin
Add basal insulin
 - most effective
Intensify insulin Add glitazoneb,c Add basal insulin
Add basal or intensify insulin





 - no hypoglycaemia
HbA1c >7%
No YesaHbA1c >7% No Yes
aHbA1c >7% No Yes
aHbA1c >7%
No YesaHbA1c >7% No Yes
aHbA1c >7%
Fig. 1 American Diabetes Association and European Association for the
Study of Diabetes consensus approach for the treatment of hyperglycemia
[40]. Reinforce lifestyle intervention at every visit. aCheck HbA1c every 3
months until HbA1c is <7 %, and then at least every 6 months.
bAssociated with increased risk of fluid retention, congestive heart failure,
and fractures. Rosiglitazone, but probably not pioglitazone, may be
associated with an increased risk of myocardial infarction. cAlthough
three oral agents can be used, initiation and intensification of insulin
therapy is preferred based on effectiveness and lower expense. With kind
permission from Springer Science Business Media: Diabetologia. Man-
agement of hyperglycaemia in type 2 diabetes mellitus: a consensus
algorithm for the initiation and adjustment of therapy—update regarding
the thiazolidinediones, 51:2008; 8–11, Nathan, DM, Buse, JB, Davidson
MB, et al.; Fig. 1 © Springer-Verlag
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everolimus therapy including fungal, hepatitis, HIV, tuber-
culosis, and any other opportunistic infections or pulmonary
conditions. Based on results from RECORD-1, a clinical
management strategy has been outlined by an advisory
panel for the treatment of grade 1 to 4 infection (Table 4).
Patients with evidence of fungal infection should be com-
prehensively treated before everolimus initiation. If an in-
vasive systemic fungal infection is suspected during
treatment, everolimus should be immediately withdrawn
and the patient treated with an appropriate antifungal
[27,45]. For patients with hepatitis B virus infection, hepa-
titis B virus DNA should be monitored and antiviral pro-
phylactic treatment given to prevent reactivation [27,45].
Current guidelines recommend the use of high-potency
and high-genetic barrier agents to quickly suppress viremia
while reducing progression of hepatic damage and the po-
tential for developing resistant mutants [45].
General adverse events observed in the BOLERO-2 study
In addition to observing key AEs associated with mTOR
inhibitors, other AEs were observed in ≥30 % (mostly grade
1 and 2) or grade 3/4 AEs reported in ≥3 % of patients
treated with everolimus combination therapy (Table 1) [17].
Most of these AEs are typically observed when treating
cancer patients.
Fatigue
Cancer-related fatigue is defined as a distressing, persistent,
and subjective sense of tiredness or exhaustion related to
cancer or cancer treatment that is not proportional to recent
activity and interferes with usual functioning [46]. In clini-
cal trials, fatigue is frequently graded using the National
Cancer Institute Common Toxicity Criteria [47], whereas in
clinical practice, the ONS grades fatigue from 0 to 10: with
0 being no fatigue and 10 representing the worst fatigue
[48]. The ONS and National Comprehensive Cancer Net-
work identifies exercise as a key intervention for preventing
and treating cancer-related fatigue as supported by strong
clinical evidence [48]. Other measures that are suggested to
provide benefit in preventing and managing fatigue are
nutrition consultation, energy conservation and sleep thera-
py, stimulus control therapy, strategies to reduce cognitive-
emotional arousal, and progressive muscle relaxation train-
ing (e.g., relaxation breathing, yoga) [46,48].
Diarrhea
Diarrhea is a common AE associated with cancer treatment.
Nonpharmacologic and pharmacologic interventions can be
used to control diarrhea and careful serial evaluation to rule
out significant volume depletion or comorbidities that
would require specific intervention or hospitalization
[49,50]. Nonpharmacologic interventions include dietary
modifications (ceasing the consumption of alcohol and of
lactose-containing foods; eating frequent small meals) and
aggressive oral rehydration with fluids that contain wa-
ter, salt, and sugar [49,50]. Pharmacologic intervention
typically includes loperamide. More severe cases may
require hospitalization in order to provide more aggres-
sive treatments [49,50].
Dyspnea
Dyspnea is breathing discomfort of varying intensity or an
uncomfortable sensation or awareness of breathing [51,52].
The causes of the condition in a patient with advanced
cancer may be multifactorial and can be classified as indirect
tumor effects (e.g., pneumonia, anemia) or direct tumor
effects (e.g., primary/metastatic parenchymal lung involve-
ment), treatment-related factors (e.g., radiation pneumoni-
tis), or factors unrelated to cancer (e.g., comorbidities such
Table 3 Recommended clinical management strategy: noninfectious pneumonitis [22]
Grade Symptoms Management Everolimus dose modification
1 Asymptomatic (radiographic findings only) • Initiate appropriate monitoring • No dose adjustment required
2 Symptomatic, not interfering with ADLs • Rule out infection • Consider interruption of therapy until
symptoms improve to grade ≤1• Consider treatment
with corticosteroids • Reinitiate everolimus at a lower dose
• Discontinue treatment if failure to recover
within 4 weeks
3 Symptomatic, interfering with
ADLs; oxygen required
• Rule out infection • Hold treatment until recovery to grade ≤1
• Consider treatment
with corticosteroids
• Consider reinitiating everolimus at a lower
dose. If toxicity recurs at grade 3, consider
discontinuation
4 Life threatening; ventilatory support indicated • Discontinue everolimus
ADL activity of daily living
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as asthma, cardiac ischemia, or psychosocial pain). Pharma-
cologic agents may be considered and nonpharmacologic
intervention methods include patient positioning (e.g., sit-
ting upright in bed or in a chair), scheduling activities,
keeping the room cool, having gentle air flow on the patient,
promoting relaxation, and psychosocial support [53].
Anemia
Anemia, a deficiency in red blood cells (RBCs), frequently
occurs among cancer patients, and has been shown to neg-
atively impact survival and increase the risk of fatigue in
patients [54]. The European Cancer Anaemia Survey de-
fines anemia as hemoglobin levels ≤12 g/dL [55], whereas
the National Comprehensive Cancer Network guidelines
define anemia as hemoglobin levels ≤11 g/dL, or ≤2 g/dL
below baseline [56]. Transfusions with packed RBCs can be
a rapid and reliable method of treating anemia; however,
such transfusions are associated with patient risks such as
transfusion-related reactions, congestive heart failure, bac-
terial contamination, viral infections, and iron overload [56,
57]. An alternative strategy includes the use of erythropoiesis-
stimulating agent therapy. However, synthetic human recom-
binant human erythropoietin can stimulate erythropoiesis even
in patients with low RBC levels. Hence, FDA has included a
“black box” warning stating that erythropoiesis-stimulating
agents should be used only to treat chemotherapy-induced
anemia and discontinued once chemotherapy has been com-
pleted [56]. Iron supplementation is also generally required by
most patients to ensure optimal erythropoiesis [58] and
depending on iron status intravenous iron supplementation
(low molecular weight iron dextran, ferric gluconate, or iron
sucrose) administered if iron deficiency is suspected [56].
Elevated transaminases
Elevated transaminases is the general term used to describe
elevation of aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) levels; elevations of less than five
times the upper limit of normal are considered mild [59,60].
Hepatoxic medications and alcohol should be discontinued
and any conditions that may cause elevated transaminase
levels, such as diabetes, heart disease, and thyroid disease,
identified and treated accordingly [59]. For patients with
mild hepatic impairment (Child–Pugh class A), everolimus
dose should be reduced to 7.5 mg/day. For moderate hepatic
impairment (Child–Pugh class B), everolimus dose should
be reduced to 5 mg/day [22]. In severely hepatic impaired
Table 4 Recommended clinical management strategy: infections [22, 27]
Grade Description Intervention Everolimus dose adjustment
1 None • Institute adequate treatment of infection
with antibiotics, as appropriate
• If toxicity is tolerable, no dose adjustment
required
• Perform culture and be aware of
atypical infections
• Initiate appropriate medical therapy and
monitor
2 Localized infection, with local
intervention indicated
• If toxicity is tolerable, no dose adjustment
required
• In patients who test positive for hepatitis
B surface antigen, consider prophylaxis
with entecavir or tenofovir
• Initiate appropriate medical therapy and
monitor
• If toxicity becomes intolerable, temporary
dose interruption until recovery to grade ≤1.
Reinitiate everolimus at the same dose
• If toxicity recurs at grade 2, interrupt
everolimus until recovery to grade ≤1.
Reinitiate everolimus at a lower dose
3 IV antibiotic, antifungal, or antiviral
intervention indicated; interventional
radiology or surgery indicated
• Provide IV antibiotic, antifungala, or
antiviral therapy; institute additional
interventions as for grade 1
• Temporary dose interruption until recovery
to grade ≤1
• Initiate appropriate medical therapy and
monitor
• Consider reinitiating everolimus at a lower
dose. If toxicity recurs at grade 3, consider
discontinuation
4 Life-threatening consequences such as
septic shock, hypotension, acidosis,
or necrosis
• Provide appropriate standard
therapy, as for grade 1
• Discontinue everolimus
IV intravenous
a If diagnosis of invasive systemic fungal infection is made, everolimus therapy should be promptly and permanently discontinued. Avoid
coadministration of everolimus with strong cytochrome 3A4 inhibitors
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patients (Child–Pugh class C), a dose of 2.5 mg/day may be
administered if the desired benefit outweighs the risk [22].
Conclusions
The oral mTOR inhibitor everolimus has demonstrated
significant clinical efficacy in women with advanced
HR-positive BC. In this patient population, everolimus
is generally well tolerated, and treatment-related AEs
are manageable with appropriate care. The critical and
diverse roles of the health care provider should not be
underestimated and include the responsibilities of patient
education, early AE identification, pretreatment plan-
ning, monitoring during therapy, and effective treatment
when AEs occur. AEs observed in patients with BC appear
to be consistent with those in patients with RCC, for which
everolimus is already approved and used routinely in the
clinic. As the application of everolimus in the treatment of
cancer expands, appropriate management of treatment-related
AEs will be fundamental to improving patient quality of life
and treatment outcomes.
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